These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15056476)

  • 1. Glutamate and anxiety.
    Bergink V; van Megen HJ; Westenberg HG
    Eur Neuropsychopharmacol; 2004 May; 14(3):175-83. PubMed ID: 15056476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate receptor ligands as anxiolytics.
    Chojnacka-Wójcik E; Kłodzinska A; Pilc A
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1112-9. PubMed ID: 11892923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate-stimulated release of norepinephrine in hippocampal slices of animal models of attention-deficit/hyperactivity disorder (spontaneously hypertensive rat) and depression/anxiety-like behaviours (Wistar-Kyoto rat).
    Howells FM; Russell VA
    Brain Res; 2008 Mar; 1200():107-15. PubMed ID: 18295191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.
    Mathew SJ; Price RB; Charney DS
    Am J Med Genet C Semin Med Genet; 2008 May; 148C(2):89-98. PubMed ID: 18412102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction.
    Tzschentke TM
    Amino Acids; 2002; 23(1-3):147-52. PubMed ID: 12373529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood disorders: regulation by metabotropic glutamate receptors.
    Pilc A; Chaki S; Nowak G; Witkin JM
    Biochem Pharmacol; 2008 Mar; 75(5):997-1006. PubMed ID: 18164691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug mechanisms in anxiety.
    Bourin M; Hascoët M
    Curr Opin Investig Drugs; 2001 Feb; 2(2):259-65. PubMed ID: 11816841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A; Pilc A
    Pharmacol Ther; 2007 Jul; 115(1):116-47. PubMed ID: 17582504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?
    Pitsikas N
    Eur J Pharmacol; 2014 Jan; 723():181-4. PubMed ID: 24361306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
    Swanson CJ; Bures M; Johnson MP; Linden AM; Monn JA; Schoepp DD
    Nat Rev Drug Discov; 2005 Feb; 4(2):131-44. PubMed ID: 15665858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future directions in anxiolytic pharmacotherapy.
    Kunovac JL; Stahl SM
    Psychiatr Clin North Am; 1995 Dec; 18(4):895-909. PubMed ID: 8748388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response properties of antral mechanosensitive afferent fibers and effects of ionotropic glutamate receptor antagonists.
    Sengupta JN; Petersen J; Peles S; Shaker R
    Neuroscience; 2004; 125(3):711-23. PubMed ID: 15099685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
    Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A
    Neuropharmacology; 2007 Feb; 52(2):306-12. PubMed ID: 17020774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in glutamate and anxiety.
    Riaza Bermudo-Soriano C; Perez-Rodriguez MM; Vaquero-Lorenzo C; Baca-Garcia E
    Pharmacol Biochem Behav; 2012 Feb; 100(4):752-74. PubMed ID: 21569789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article.
    Chizh BA
    Amino Acids; 2002; 23(1-3):169-76. PubMed ID: 12373533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models.
    Harvey BH; Shahid M
    Pharmacol Biochem Behav; 2012 Feb; 100(4):775-800. PubMed ID: 21708184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabotropic actions of kainate receptors in the CNS.
    Rodríguez-Moreno A; Sihra TS
    J Neurochem; 2007 Dec; 103(6):2121-35. PubMed ID: 18070252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
    Carroll FI
    Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of NMDA and AMPA/kainate receptor antagonists on nitric oxide production in rat brain following intrahippocampal injection.
    Radenovic L; Selakovic V
    Brain Res Bull; 2005 Sep; 67(1-2):133-41. PubMed ID: 16140172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.